Summary

Watch as investigator Rao Ravinder Singh summarises the findings from the MyVal study, which he presented at EuroPCR 2018. The first-in-man study reveals 30-day clinical and echocardiographic results of a next-generation balloon-expandable transcatheter aortic valve replacement (TAVR) system in 30 patients with severe stenosis of the native aortic valve. R.R. Singh outlines the technology of the valve, and its performance immediately post-procedure and at 30 days in relation to mean gradient, pacemaker rate, and mild, moderate, and severe paravalvular leak. Find out his conclusions on its safety in these patients…

Click here for more information